Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival.

Autor: Santoni M; Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100 Macerata, Italy. Electronic address: mattymo@alice.it., Monteiro FSM; Latin American Cooperative Oncology Group - LACOG, Brazil; Oncology and Hematology Department, Hospital Santa Lucia, SHLS 716 Cj. C, Brasília, DF 70390-700, Brazil., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italy., Abahssain H; Medicine and Pharmacy Faculty, National Institute of Oncology, Medical Oncology Unit, Mohamed V University, Rabat, Morocco., Aurilio G; Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan, Italy., Molina-Cerrillo J; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain., Myint ZW; Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA; Division of Medical Oncology, University of Kentucky, Lexington, KY, USA., Zabalza IO; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain., Battelli N; Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100 Macerata, Italy., Grande E; Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
Jazyk: angličtina
Zdroj: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2022 Aug; Vol. 176, pp. 103731. Date of Electronic Publication: 2022 Jun 17.
DOI: 10.1016/j.critrevonc.2022.103731
Abstrakt: Statins are commonly prescribed to reduce plasma cholesterol levels and risk of cardiovascular events and mortality. Statin exposure may have cancer-preventive properties in some solid tumors, including Renal Cell Carcinoma (RCC). Emerging evidences show that statins can inhibit RCC cell growth by inducing cell cycle arrest and apoptosis in a dose- and time-dependent manner. In addition, statins inhibit the phosphorylation of AKT, mammalian target of rapamycin (mTOR), and ERK leading to reduced motility of RCC cells. Interestingly, the potential impact of concomitant statin intake has been recently evaluated in RCC patients treated by targeted therapy or immunotherapy. In this review, we illustrate the most recent data on the preclinical activity of statins in Renal Cell Carcinoma models and discuss the impact of their use on the prevention and survival of patients affected by this tumor.
(Copyright © 2022 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: